{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:01:13Z","timestamp":1780203673920,"version":"3.54.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.7759\/cureus.109947","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:32:15Z","timestamp":1780201935000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Compliance Through Local Anesthesia in Extended-Release Buprenorphine Therapy: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Sina","family":"Radparvar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Opioid overdose deaths. National trends and variation by demographics and states. (2026). Accessed: April 9, 2026: https:\/\/www.kff.org\/mental-health\/opioid-overdose-deaths-national-trends-and-variation-by-demographics-and-states\/."},{"key":"ref2","unstructured":"Drug overdose deaths in the United States, 2003-2023. (2024). Accessed. April 9, 2026: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db522.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001520","article-title":"Transition to extended-release buprenorphine injectable within seven days for opioid use disorder treatment: a scoping narrative","volume":"19","author":"Siu JT","year":"2025","unstructured":"Siu JT, Lau A, Wong JS, Machado J, Azar P. Transition to extended-release buprenorphine injectable within seven days for opioid use disorder treatment: a scoping narrative. J Addict Med. 2025, 19:371-80. 10.1097\/ADM.0000000000001520","journal-title":"J Addict Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S155843","article-title":"Depot buprenorphine injection in the management of opioid use disorder: from development to implementation","volume":"10","author":"Ling W","year":"2019","unstructured":"Ling W, Shoptaw S, Goodman-Meza D. Depot buprenorphine injection in the management of opioid use disorder: from development to implementation. Subst Abuse Rehabil. 2019, 10:69-78. 10.2147\/SAR.S155843","journal-title":"Subst Abuse Rehabil"},{"key":"ref5","unstructured":"Indivior announces FDA approval of label changes for Sublocade (buprenorphine extended-release) injection. (2025). Accessed. March 10, 2026: https:\/\/www.indivior.com\/latest\/news\/2025\/indivior-announces-fda-approval-of-label-changes-for-sublocade-injection."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108661","article-title":"Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine","volume":"136","author":"Stein MD","year":"2022","unstructured":"Stein MD, VanNoppen D, Herman DS, Anderson BJ, Conti M, Bailey GL. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine. J Subst Abuse Treat. 2022, 136:108661. 10.1016\/j.jsat.2021.108661","journal-title":"J Subst Abuse Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight BR","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, et al.. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019, 393:778-90. 10.1016\/S0140-6736(18)32259-1","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn AC","year":"2020","unstructured":"Andorn AC, Haight BR, Shinde S, et al.. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol. 2020, 40:231-9. 10.1097\/JCP.0000000000001195","journal-title":"J Clin Psychopharmacol"},{"key":"ref9","unstructured":"Sublocade (buprenorphine) extended-release injection for subcutaneous use. (2025). Accessed. March 29, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209819s028lbl.pdf."},{"key":"ref10","unstructured":"Brixadi (buprenorphine) extended-release injection for subcutaneous use. (2025). Accessed. March 29, 2026: https:\/\/www.brixadi.com\/pdfs\/brixadi-prescribing-information.pdf."},{"key":"ref11","unstructured":"Clinical updates on the use of injectable medications for opioid use disorder (MoUD). (2021). Accessed. Aprill 11, 2026: https:\/\/sites.rutgers.edu\/mat-coe\/wp-content\/uploads\/sites\/473\/2021\/05\/Clinical-Updates-on-the-Use-of-Injectable-Medi...."},{"key":"ref12","unstructured":"Using Sublocade in your MAT program. (2020). Accessed. March 30, 2026: https:\/\/www.careinnovations.org\/wp-content\/uploads\/Sublocade-Presentation_060820.pdf."},{"key":"ref13","article-title":"Neuroanatomy, Dorsal Root Ganglion","author":"Ahimsadasan N","year":"2026","unstructured":"Ahimsadasan N, Reddy V, Khan Suheb MZ, Kumar A. Neuroanatomy, Dorsal Root Ganglion. StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019898","article-title":"A review of the mechanism of the central analgesic effect of lidocaine","volume":"99","author":"Yang X","year":"2020","unstructured":"Yang X, Wei X, Mu Y, Li Q, Liu J. A review of the mechanism of the central analgesic effect of lidocaine. Medicine (Baltimore). 2020, 99:e19898. 10.1097\/MD.0000000000019898","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102733","article-title":"Molecular mechanisms of lidocaine","volume":"69","author":"Karnina R","year":"2021","unstructured":"Karnina R, Arif SK, Hatta M, Bukhari A. Molecular mechanisms of lidocaine. Ann Med Surg (Lond). 2021, 69:102733. 10.1016\/j.amsu.2021.102733","journal-title":"Ann Med Surg (Lond)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31829ad1e2","article-title":"Minimizing the pain of local anesthesia injection","volume":"132","author":"Strazar AR","year":"2013","unstructured":"Strazar AR, Leynes PG, Lalonde DH. Minimizing the pain of local anesthesia injection. Plast Reconstr Surg. 2013, 132:675-84. 10.1097\/PRS.0b013e31829ad1e2","journal-title":"Plast Reconstr Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.15444","article-title":"Lidocaine and pain management in the emergency department: a review article","volume":"4","author":"Golzari SE","year":"2014","unstructured":"Golzari SE, Soleimanpour H, Mahmoodpoor A, Safari S, Ala A. Lidocaine and pain management in the emergency department: a review article. Anesth Pain Med. 2014, 4:e15444. 10.5812\/aapm.15444","journal-title":"Anesth Pain Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001279","article-title":"Finer needles reduce pain associated with injection of local anesthetic using a minimal insertion injection technique","volume":"44","author":"Zelickson BR","year":"2018","unstructured":"Zelickson BR, Goldberg LH, Rubenzik MK, Wu WJ. Finer needles reduce pain associated with injection of local anesthetic using a minimal insertion injection technique. Dermatol Surg. 2018, 44:204-8. 10.1097\/DSS.0000000000001279","journal-title":"Dermatol Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2009.0020","article-title":"A comparison of a refrigerant and a topical anesthetic gel as preinjection anesthetics: a clinical evaluation","volume":"140","author":"Kosaraju A","year":"2009","unstructured":"Kosaraju A, Vandewalle KS. A comparison of a refrigerant and a topical anesthetic gel as preinjection anesthetics: a clinical evaluation. J Am Dent Assoc. 2009, 140:68-72. 10.14219\/jada.archive.2009.0020","journal-title":"J Am Dent Assoc"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.7547\/87507315-88-2-73","article-title":"Clinical comparison of preinjection anesthetics","volume":"88","author":"Plotkin S","year":"1998","unstructured":"Plotkin S. Clinical comparison of preinjection anesthetics. J Am Podiatr Med Assoc. 1998, 88:73-9.","journal-title":"J Am Podiatr Med Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.088","article-title":"Buffered lidocaine 1%\/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: a double-blind, randomized, placebo-controlled, crossover trial","volume":"83","author":"Vent A","year":"2020","unstructured":"Vent A, Surber C, Graf Johansen NT, et al.. Buffered lidocaine 1%\/epinephrine 1:100,000 with sodium bicarbonate (sodium hydrogen carbonate) in a 3:1 ratio is less painful than a 9:1 ratio: a double-blind, randomized, placebo-controlled, crossover trial. J Am Acad Dermatol. 2020, 83:159-65. 10.1016\/j.jaad.2019.09.088","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/08990220600700925","article-title":"Pain following controlled cutaneous insertion of needles with different diameters","volume":"23","author":"Arendt-Nielsen L","year":"2006","unstructured":"Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006, 23:37-43. 10.1080\/08990220600700925","journal-title":"Somatosens Mot Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000003730","article-title":"How to minimize the pain of local anesthetic injection for wide awake surgery","volume":"9","author":"Joukhadar N","year":"2021","unstructured":"Joukhadar N, Lalonde D. How to minimize the pain of local anesthetic injection for wide awake surgery. Plast Reconstr Surg Glob Open. 2021, 9:e3730. 10.1097\/GOX.0000000000003730","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(98)70404-9","article-title":"Repetitive pinching of the skin during lidocaine infiltration reduces patient discomfort","volume":"39","author":"Fosko SW","year":"1998","unstructured":"Fosko SW, Gibney MD, Harrison B. Repetitive pinching of the skin during lidocaine infiltration reduces patient discomfort. J Am Acad Dermatol. 1998, 39:74-8. 10.1016\/s0190-9622(98)70404-9","journal-title":"J Am Acad Dermatol"},{"key":"ref25","article-title":"Optimizing local anesthesia use in office-based dermatologic procedures","volume":"18","author":"Ceilley RI","year":"2025","unstructured":"Ceilley RI, Sureshbabu S. Optimizing local anesthesia use in office-based dermatologic procedures. J Clin Aesthet Dermatol. 2025, 18:22-3.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787.x16_Substance_Related_Disorders#sec-7","article-title":"Opioid-related disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Opioid-related disorders.  Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association , Washington, D.C.; 2022. 10.1176\/appi.books.9780890425787.x16_Substance_Related_Disorders#sec-7"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson DR","year":"2003","unstructured":"Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003, 35:253-9. 10.1080\/02791072.2003.10400007","journal-title":"J Psychoactive Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9708","article-title":"Extended-release buprenorphine and its evaluation with patient-reported outcomes","volume":"4","author":"Compton WM","year":"2021","unstructured":"Compton WM, Volkow ND. Extended-release buprenorphine and its evaluation with patient-reported outcomes. JAMA Netw Open. 2021, 4:e219708. 10.1001\/jamanetworkopen.2021.9708","journal-title":"JAMA Netw Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104748","article-title":"Retention and dropout from sublingual and extended-release buprenorphine treatment: a comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States","volume":"138","author":"Ivasiy R","year":"2025","unstructured":"Ivasiy R, Madden LM, Johnson KA, et al.. Retention and dropout from sublingual and extended-release buprenorphine treatment: a comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States. Int J Drug Policy. 2025, 138:104748. 10.1016\/j.drugpo.2025.104748","journal-title":"Int J Drug Policy"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104390","article-title":"96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial","volume":"127","author":"Farrell M","year":"2024","unstructured":"Farrell M, Shahbazi J, Chambers M, et al.. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024, 127:104390. 10.1016\/j.drugpo.2024.104390","journal-title":"Int J Drug Policy"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/add.70105","article-title":"A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine","volume":"120","author":"Deng C","year":"2025","unstructured":"Deng C, Oviedo E, Fishman M, Burgess-Hull A. A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine. Addiction. 2025, 120:2127-33. 10.1111\/add.70105","journal-title":"Addiction"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017-21","volume":"42","author":"Andraka-Christou B","year":"2023","unstructured":"Andraka-Christou B, Simon KI, Bradford WD, Nguyen T. Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017-21. Health Aff (Millwood). 2023, 42:658-64. 10.1377\/hlthaff.2022.01513","journal-title":"Health Aff (Millwood)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001320","article-title":"Provider perceptions toward extended-release buprenorphine for treatment of opioid use disorder","volume":"18","author":"Reddy IA","year":"2024","unstructured":"Reddy IA, Audet CM, Reese TJ, Peek G, Marcovitz D. Provider perceptions toward extended-release buprenorphine for treatment of opioid use disorder. J Addict Med. 2024, 18:540-5. 10.1097\/ADM.0000000000001320","journal-title":"J Addict Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S266838","article-title":"Patient-reported outcomes, experiences and satisfaction with weekly and monthly injectable prolonged-release buprenorphine","volume":"11","author":"Parsons G","year":"2020","unstructured":"Parsons G, Ragbir C, D'Agnone O, Gibbs A, Littlewood R, Hard B. Patient-reported outcomes, experiences and satisfaction with weekly and monthly injectable prolonged-release buprenorphine. Subst Abuse Rehabil. 2020, 11:41-7. 10.2147\/SAR.S266838","journal-title":"Subst Abuse Rehabil"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00288-4","article-title":"Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study","volume":"17","author":"Cheng A","year":"2022","unstructured":"Cheng A, Badolato R, Segoshi A, et al.. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addict Sci Clin Pract. 2022, 17:4. 10.1186\/s13722-022-00288-4","journal-title":"Addict Sci Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494815-enhancing-compliance-through-local-anesthesia-in-extended-release-buprenorphine-therapy-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:32:37Z","timestamp":1780201957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494815-enhancing-compliance-through-local-anesthesia-in-extended-release-buprenorphine-therapy-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.109947","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}